QIAGEN OmicSoft and Biomedical Knowledge Base
Exploring drug response in low-grade glioma
284 views
See how Dr, Nilson from QIAGEN Digital Insights navigates an interesting intersection of the tumor microenvironment, mutation status, and gene expression to identify plausible activators affecting bevacizumab targets in low-grade glioma.
In this webinar participants will learn about
In this webinar participants will learn about
- The tools used to identify key genes in LGG
- How we choose specific gene alterations
- The intersection between immune response tumor mutations
- How we identify other key genes of interest
- How we build a network tying all these elements together
Related videos
QIAGEN OmicSoft and Biomedical Knowledge Base
Checkpoint inhibitors investigation in context of biomarkers, drug targets and pathways using...
This training will focus on how QIAGEN Omicsoft Studio and IPA can be used to...
QIAGEN IPA
Systems analysis of cancer cell lines for drug target discovery
Cancer cell line models have been a cornerstone of cancer research for...
QIAGEN OmicSoft and Biomedical Knowledge Base
Public single-cell RNA-seq data investigation using QIAGEN OmicSoft and Ingenuity Pathway Analysis
Single-cell RNA-sequencing (scRNA-seq) is widely used to investigate tissue...